quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:49:41·134d
INSIDERFiling
Adverum Biotechnologies Inc. logo

CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

ADVM· Adverum Biotechnologies Inc.
Health Care
Original source

Companies

  • ADVM
    Adverum Biotechnologies Inc.
    Health Care

Recent analyst ratings

  • Nov 17UpdateH.C. Wainwright-
  • Jun 25UpdateOppenheimer$25.00
  • Apr 30UpdateH.C. Wainwright$30.00
  • Jul 7UpdateTruist$4.00
  • Jul 23UpdateCantor Fitzgerald-
  • Jul 23UpdateCantor Fitzgerald$3.00

Related

  • SEC125d
    SEC Form 15-12G filed by Adverum Biotechnologies Inc.
  • SEC133d
    SEC Form EFFECT filed by Adverum Biotechnologies Inc.
  • SEC133d
    SEC Form EFFECT filed by Adverum Biotechnologies Inc.
  • SEC133d
    SEC Form EFFECT filed by Adverum Biotechnologies Inc.
  • INSIDER134d
    CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
  • INSIDER134d
    Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
  • INSIDER134d
    CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
  • INSIDER134d
    CHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022